News publications and other organizations are encouraged to reuse Direct Relief-published content for free under a Creative Commons License (Attribution-Non-Commercial-No Derivatives 4.0 International), given the republisher complies with the requirements identified below.

When republishing:

  • Include a byline with the reporter’s name and Direct Relief in the following format: "Author Name, Direct Relief." If attribution in that format is not possible, include the following language at the top of the story: "This story was originally published by Direct Relief."
  • If publishing online, please link to the original URL of the story.
  • Maintain any tagline at the bottom of the story.
  • With Direct Relief's permission, news publications can make changes such as localizing the content for a particular area, using a different headline, or shortening story text. To confirm edits are acceptable, please check with Direct Relief by clicking this link.
  • If new content is added to the original story — for example, a comment from a local official — a note with language to the effect of the following must be included: "Additional reporting by [reporter and organization]."
  • If republished stories are shared on social media, Direct Relief appreciates being tagged in the posts:
    • Twitter (@DirectRelief)
    • Facebook (@DirectRelief)
    • Instagram (@DirectRelief)

Republishing Images:

Unless stated otherwise, images shot by Direct Relief may be republished for non-commercial purposes with proper attribution, given the republisher complies with the requirements identified below.

  • Maintain correct caption information.
  • Credit the photographer and Direct Relief in the caption. For example: "First and Last Name / Direct Relief."
  • Do not digitally alter images.

Direct Relief often contracts with freelance photographers who usually, but not always, allow their work to be published by Direct Relief’s media partners. Contact Direct Relief for permission to use images in which Direct Relief is not credited in the caption by clicking here.

Other Requirements:

  • Do not state or imply that donations to any third-party organization support Direct Relief's work.
  • Republishers may not sell Direct Relief's content.
  • Direct Relief's work is prohibited from populating web pages designed to improve rankings on search engines or solely to gain revenue from network-based advertisements.
  • Advance permission is required to translate Direct Relief's stories into a language different from the original language of publication. To inquire, contact us here.
  • If Direct Relief requests a change to or removal of republished Direct Relief content from a site or on-air, the republisher must comply.

For any additional questions about republishing Direct Relief content, please email the team here.

Direct Relief Prepares for Covid-19 Vaccine Distribution, Investing $2.5 Million to Expand Cold-Chain Capacity



Direct Relief's California headquarters features a 155,000-square-foot pharmaceutical warehouse, the largest in the U.S. run by a charity, and includes validated cold-storage capacity, pictured here in 2019, for vaccines and other temperature sensitive medications. (Lara Cooper/Direct Relief)

Direct Relief has committed $2.5 million to expand its cold-chain pharmaceutical distribution capacity, preparing to assist public health authorities and other health organizations in the global distribution of Covid-19 vaccines.

The $2.5 million investment aims to triple Direct Relief’s medical refrigeration and freezer capacity. Direct Relief’s current validated-for-vaccine cold-storage warehousing can hold up to 40 million doses of vaccine in 10-dose-per-vial packaging within the typical 2-8-degree Celsius temperature range but lacks larger-volume freezer capacity that some Covid-19 vaccines may require.

The organization is in discussions with national and state health authorities, the National Association of Boards of Pharmacy, and pharmaceutical donors about Covid-19 vaccine distribution plans.

Direct Relief is one of the world’s primary channels for distributing donated charitable medications—including vaccines and other cold-chain medications (those requiring constant, carefully controlled refrigeration)—to people who otherwise would not have access. In the United States, Direct Relief is a central conduit for distributing such medications to nonprofit safety-net providers, including community health centers. These providers are critical in reaching underserved communities, and specifically people of color, who have been disproportionally affected by Covid-19.

Direct Relief’s state-of-the-art pharmaceutical distribution center, which opened in 2018 in California, is one of 665 facilities in the United States accredited by the National Association of Boards of Pharmacy as an Accredited Drug Distributor and is the only one operated by a global humanitarian aid organization.

While the specific temperature-management requirements for various Covid-19 vaccines remain unknown, Direct Relief believes global cold-chain capacity is far below what is needed for rapid, mass-vaccination efforts to immunize the U.S. population, much less the global population.

“Direct Relief is taking this step with urgency, recognizing the pressures that exist in getting approved vaccine to people who need it in a safe, secure way,” said Thomas Tighe, Direct Relief President and CEO. “Existing cold-chain channels were not built to support this scale of activity. The situation echoes the severe challenges that arose with the allocation and distribution of PPE—which did not require specialized licensing to handle, store, or track, as do prescription drugs and vaccines.”

Direct Relief has extensive experience working with the world’s largest medical manufacturers to distribute cold-chain prescription drugs, vaccines, and biologic therapies connected with humanitarian and emergency-response efforts.

In the fiscal year ended June 30, Direct Relief completed 2,103 cold-chain deliveries of such products, managing end-to-end distribution to health facilities across the United States and 33 other countries. These deliveries included 738,000 vials of insulin from Eli Lilly, Novo Nordisk, and Sanofi for patients with Type-1 and Type-2 diabetes; cancer treatment drugs from Amgen, Teva, Takeda, and Baxter; blood-clotting hemophilia treatments from Bayer, Takeda, Pfizer, and Kedrion Biopharma; and biologic therapies from Takeda and Biogen for patients with rare genetic diseases.

Direct Relief has been responding expansively to Covid-19 since reports first arose in January of cases in Wuhan, China, and the Western United States. Since Direct Relief’s first Covid-19 aid delivery on Jan. 27, the organization sent 21,083 medical aid shipments to 2,786 health facilities in 54 U.S. states and territories and 88 countries. These shipments contained 3.2 million lbs. (1,600 tons) of medical essentials, including more than 38 million N95 and surgical masks, more than 7 million gloves, more than 1 million face shields, and tens of thousands of protective suits and other items to help safeguard health workers and care for patients, as well as including 76.9 million Defined Daily Doses of medications, with a value of $747.6 million (wholesale acquisition cost).

“Because Direct Relief is a public-benefit nonprofit with the specialized licensing, capacity, and experience required for cold-chain vaccine distribution, we will do whatever we possibly can to pitch in and backstop public agencies that have their hands more than full,” Tighe said. “We also want to ensure that those most in need, whom our organization supports every day and have suffered disproportionate effects from Covid-19, have a channel to support them.”

Giving is Good Medicine

You don't have to donate. That's why it's so extraordinary if you do.